Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance JJ Borg, G Aislaitner, M Pirozynski, S Mifsud Drug safety 34, 187-197, 2011 | 140 | 2011 |
Actions of pyrethroid insecticides on sodium currents, action potentials, and contractile rhythm in isolated mammalian ventricular myocytes and perfused hearts CI Spencer, KH Yuill, JJ Borg, JC Hancox, RZ Kozlowski Journal of Pharmacology and Experimental Therapeutics 298 (3), 1067-1082, 2001 | 104 | 2001 |
Actions of pyrethroid insecticides on sodium currents, action potentials, and contractile rhythm in isolated mammalian ventricular myocytes and perfused hearts CI Spencer, KH Yuill, JJ Borg, JC Hancox, RZ Kozlowski Journal of Pharmacology and Experimental Therapeutics 298 (3), 1067-1082, 2001 | 104 | 2001 |
Regulatory evaluation of Glybera in Europe—two committees, one mission D Melchiorri, L Pani, P Gasparini, G Cossu, J Ancans, JJ Borg, C Drai, ... Nature reviews Drug discovery 12 (9), 719-719, 2013 | 84 | 2013 |
Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use P Salmikangas, M Menezes-Ferreira, I Reischl, A Tsiftsoglou, J Kyselovic, ... Regenerative medicine 10 (1), 65-78, 2015 | 63 | 2015 |
European Union pharmacovigilance capabilities: potential for the new legislation JJ Borg, A Tanti, D Kouvelas, C Lungu, M Pirozynski, A Serracino-Inglott, ... Therapeutic advances in drug safety 6 (4), 120-140, 2015 | 44 | 2015 |
In support of the European Union biosimilar framework CK Schneider, JJ Borg, F Ehmann, N Ekman, E Heinonen, K Ho, ... Nature biotechnology 30 (8), 745-748, 2012 | 40 | 2012 |
Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene—without QT interval prolongation KH Yuill, JJ Borg, JM Ridley, JT Milnes, HJ Witchel, AA Paul, ... Biochemical and biophysical research communications 318 (2), 556-561, 2004 | 32 | 2004 |
Cardiac chloride channels: physiology, pharmacology and approaches for identifying novel modulators of activity AW Mulvaney, CI Spencer, S Culliford, JJ Borg, SG Davies, RZ Kozlowski Drug discovery today 5 (11), 492-505, 2000 | 32 | 2000 |
Inhibitory effects of the antiestrogen agent clomiphene on cardiac sarcolemmal anionic and cationic currents JJ Borg, KH Yuill, JC Hancox, IC Spencer, RZ Kozlowski Journal of Pharmacology and Experimental Therapeutics 303 (1), 282-292, 2002 | 23 | 2002 |
Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases GS Filippatos, P de Graeff, JJ Bax, JJ Borg, JGF Cleland, HJ Dargie, ... European journal of heart failure 19 (4), 449-456, 2017 | 19 | 2017 |
Where is industry getting it wrong? A review of quality concerns raised at day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing … JJ Borg, JL Robert, G Wade, G Aislaitner, M Pirozynski, E Abadie, ... Journal of Pharmacy & Pharmaceutical Sciences 12 (2), 181-198, 2009 | 18 | 2009 |
Quality issues identified during the evaluation of biosimilars by the European Medicines Agency’s Committee for Medicinal Products for Human Use M Cilia, S Ruiz, P Richardson, T Salmonson, A Serracino-Inglott, F Wirth, ... AAPS PharmSciTech 19, 489-511, 2018 | 15 | 2018 |
DIFFERENTIAL EFFECTS OF PYRETHROIDS ON VOLUME‐SENSITIVE ANION AND ORGANIC OSMOLYTE PATHWAYS SJ Culliford, JJ Borg, MJ O'Brien, RZ Kozlowski Clinical and experimental pharmacology and physiology 31 (3), 134-144, 2004 | 14 | 2004 |
Medication errors through a national pharmacovigilance database approach: a study for Malta A Tanti, M Camilleri, PV Bonanno, JJ Borg International journal of risk & safety in medicine 25 (1), 17-27, 2013 | 12 | 2013 |
Reflections on decisions made on the well-established use of medicinal products by EU regulators and the ECJ JJ Borg, A Laslop, L Pani, R Maciulaitis, D Melchiorri Scientia Pharmaceutica 82 (3), 655-664, 2014 | 11 | 2014 |
Differential pharmacology of the cardiac anionic background current IAB JJ Borg, JC Hancox, H Zhang, CI Spencer, H Li, RZ Kozlowski European journal of pharmacology 569 (3), 163-170, 2007 | 10 | 2007 |
Multimodal management as requirement for the clinical use of anticachexia drugs-a regulatory and a clinical perspective JJ Borg, SD Anker, G Rosano, A Serracino-Inglott, F Strasser Current opinion in supportive and palliative care 9 (4), 333-345, 2015 | 9 | 2015 |
Tefluthrin modulates a novel anionic background conductance (IAB) in guinea-pig ventricular myocytes JJ Borg, JC Hancox, CI Spencer, RZ Kozlowski Biochemical and biophysical research communications 292 (1), 208-215, 2002 | 9 | 2002 |
Actions of the anti‐oestrogen agent clomiphene on outward K+ currents in rat ventricular myocytes JJ Borg, JC Hancox, DS Hogg, AF James, RZ Kozlowski Clinical and experimental pharmacology and physiology 31 (1‐2), 86-95, 2004 | 7 | 2004 |